Submit a Manuscript to the Journal
Artificial Cells, Nanomedicine, and Biotechnology
For an Article Collection on
Innovative Nanomedicines for Pulmonary Vascular Diseases Management
Manuscript deadline
Article Collection Guest Advisor(s)
Dr. Zhengwei Huang,
Jinan University, China
huangzhengw@jnu.edu.cn
Dr. Binghua Wang,
Zhengzhou University, China
wbh1005@zzu.edu.cn
Dr. Xiang Lu,
Zhengzhou University, China
yxyxianglu@zzu.edu.cn
Benefits of Publishing in an Article Collection
An Article Collection is an opportunity for your research to reach the right audience. Bringing together the work of the global research community, Collections provide readers with a central place to find the latest research on emerging and important topics. They have been found to increase the discoverability and visibility of each article, as well as article-level citations.
Innovative Nanomedicines for Pulmonary Vascular Diseases Management
Pulmonary vascular diseases (PVDs), encompassing pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and other disorders associated with pulmonary vascular dysfunction and remodeling, represent a heterogeneous group of clinically important cardiopulmonary diseases. Although advances in pharmacological interventions targeting vascular tone, inflammation, abnormal cellular proliferation, and vascular remodeling, the clinical management of PVDs remains challenging, including limited therapeutic efficacy, inadequate drug delivery and bioavailability, and the difficulty of achieving precise delivery to diseased pulmonary vasculature. Nanomedicine offers promising opportunities to address these challenges through the development of functionalized nanoscale drug delivery systems that improve the physicochemical properties of therapeutics, increase local drug availability, and support multifunctional therapeutic strategies. This Article Collection aims to showcase the latest advances in nanomedicine for PVDs, with a particular focus on innovative nanodelivery platforms, stimuli-responsive nanomaterials, biomimetic nanosystems, and their translational applications, thereby promoting the development of next-generation nanotherapeutic strategies and accelerating the translation of fundamental research into clinical practice.
The complex and heterogeneous nature of PVDs presents substantial challenges for conventional pharmacological interventions, particularly in achieving sufficient drug exposure at diseased pulmonary vascular sites while minimizing off-target effects. Nanomedicine provides a promising technological platform to address these challenges by enabling the development of tailored drug delivery systems for pulmonary vascular diseases. Nanodelivery strategies can facilitate the delivery of small-molecule drugs, nucleic acids, proteins, and combination therapeutics, while improving drug solubility, stability, and bioavailability. Besides, rationally designed nanocarriers may enhance drug accumulation at relevant pulmonary sites and enable controlled or targeted drug release, thereby providing opportunities for more precise and multifunctional therapeutic interventions. Therefore, advancing nanomedicine research in PVDs is important for developing innovative therapeutic strategies, and facilitating the translation of emerging nanotherapeutic approaches toward clinical applications.
This Article Collection focuses on fundamental research, technological innovation, and translational applications of innovative nanomedicines for the management of PVDs. It aims to showcase the latest advances at the intersection of nanomaterials, biotechnology, and pulmonary vascular disease research, while promoting the development and application of next-generation nanotherapeutic strategies. The Collection welcomes contributions covering, but not limited to, the design and development of novel nanomedicines and nanodelivery systems, biomimetic nanoplatforms, polymeric nanoparticles, liposomes, nanomicelles, exosomes, and other emerging nanocarriers; stimuli-responsive nanomaterials; pulmonary-targeted and inhalation-based drug delivery technologies; controlled and combination drug delivery strategies; as well as the pharmacokinetics, biosafety, computer-aided formulation design, advanced manufacturing technologies, and clinical translation of nanomedicines. Studies addressing the pathogenesis of PVDs, emerging therapeutic targets, the mechanisms of action of nanomedicines, and their applications in precision medicine are also within the scope of this Collection. We warmly welcome Original Research articles, Reviews, Mini-reviews, and Perspective articles that advance the fundamental understanding, technological innovation, and clinical application of nanomedicine for the precision management of PVDs.
Please contact Haoyang Yi (Commissioning Editor) at Haoyang.yi@taylorandfrancis.com with any queries and discount codes regarding this Article Collection.
Guest Advisors
Dr. Zhengwei Huang
Dr. Huang is a Ph.D. supervisor in Jinan University, whose research interests are nanomedicine, pulmonary drug delivery and respiratory disease therapy. In recent years, he received 21 scientific fundings, including two from National Natural Science Foundation of China. He has published 85 SCI-indexed papers, with an H-index of 26. Dr. Huang also applies for 9 Chinese patents, 8 issued. He been elected as Wiley Top Cited Article Author and Outstanding Reviewer by Pharmaceutics.
Dr. Binghua Wang
Dr. Binghua Wang is an Associate Professor and Master supervisor at the School of Pharmaceutical Sciences, Zhengzhou University, whose research interests focus on nanomedicine, inhalation therapy, pulmonary drug delivery, and respiratory disease treatment. In recent years, she received 5 scientific fundings and has published more than 10 SCI-indexed papers in high-impact journals such as Advanced Materials, ACS Nano, and Science Advances, with an H-index of 18. Dr. Wang also applies for 7 Chinese patents, 4 issued.
Dr. Xiang Lu
Dr. Xiang Lu is a Master supervisor in the Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, whose research interests are pulmonary drug delivery, inhalation therapy, and pulmonary fibrosis treatment. He has published 11 SCI-indexed papers in high-impact journals. Dr. Lu also applies for 11 Chinese patents, 2 issued.
Benefits of publishing open access within Taylor & Francis
Sustained readership
Publishing in an Article Collection ensures your research reaches a wide and engaged audience, driving long-term readership and citation impact.
Enhanced visibility
Gain recognition by showcasing your work in a trusted and reputable platform, amplifying your research’s visibility and influence.
Trends and methodologies
Connect with emerging topics and methodologies, positioning your research at the forefront of innovation and shaping the future of your field.
Support
Receive expert guidance at every stage of the publishing process from our experienced journal team, ensuring a seamless experience.
Network
Expand your professional network by collaborating with leading researchers from around the world, fostering interdisciplinary connections.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this Collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.